During Wednesday’s current trade, ONEOK, Inc. (NYSE:OKE)’s shares decreased -0.89%, to $41.20.
ONEOK (OKE) the company declared and paid three dividends, and in January 2015, raised the dividend 7 percent.
Shareholders approved the following proposals:
- Election of three directors to the ONE Gas Board of Directors each for a three-year term;
- Selection of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for 2015;
- Performance aims and approval of the company’s executive compensation plan on an advisory basis; and
- Advisory votes on executive compensation will be conducted on a yearly basis.
ONE Gas, Inc. (OGS) is a natural gas distribution company and the successor to the company founded in 1906 as Oklahoma Natural Gas Company, which became ONEOK, Inc. (OKE) in 1980. On January 31, 2014, ONE Gas officially separated from ONEOK into a stand-alone, 100 percent regulated, publicly traded natural gas utility.
ONE Gas trades on the New York Stock Exchange under the symbol “OGS,” and is comprised of in the S&P MidCap 400 Index.
ONE Gas provides natural gas distribution services to more than 2 million customers in Oklahoma, Kansas and Texas. ONE Gas is one of the largest publicly traded, 100 percent regulated, natural gas utilities in the United States.
ONE Gas is headquartered in Tulsa, Okla., and its companies comprise the largest natural gas distributor in Oklahoma and Kansas, and the third largest in Texas, in terms of customers.
ONEOK, Inc. engages in the gathering, processing, storage, and transportation of natural gas in the United States. It operates in Natural Gas Gathering and Processing, Natural Gas Liquids, and Natural Gas Pipelines segments.
Credit Suisse Group AG (ADR) (NYSE:CS)’s shares jumped 3.05% to $27.69, during the current trading session Wednesday’s.
The Credit Suisse LAB Index was up 0.83% in May.
The Credit Suisse Liquid Alternative Beta Index (“CSLAB”), which aims to reflect the performance of the overall hedge fund industry, finished up 0.83% in May. The Long/Short Equity strategy was the strongest performer, finishing up 1.28% in May. The Managed Futures strategy remains the highest performer year-to-date, up 7.81%.
Credit Suisse Group AG, together with its auxiliaries, provides various financial services to private, corporate, institutional, government clients, and high-net-worth individuals, in addition to affluent and retail clients worldwide. The company operates through two segments, Private Banking & Wealth Administration and Investment Banking. The Private Banking & Wealth Administration segment offers a range of advice and financial solutions, counting structured advisory to high-net-worth clients; banking products, such as lending, cash and liquidity administration, trade finance, ship and aviation finance, corporate finance, investment solutions, custody, and asset and liability administration; and investment solutions and services to pension funds, governments, foundations and endowments, corporations, and individuals.
In a mid-morning trade, Celldex Therapeutics, Inc. (NASDAQ:CLDX)‘s shares climbed 1.01%, to $27.93.
Celldex Therapeutics, Inc. CLDX presented positive results from a phase II study (ReACT) on Rintega at the annual meeting of the American Society of Clinical Oncology. Rintega, a therapeutic vaccine, is being developed for the treatment of patients suffering from EGFRvIII-positive, recurrent glioblastoma (GBM).
The randomized, controlled, double-blind phase II exploratory study was conducted with the aim of determining whether Rintega when added to standard-of-care treatment like Roche’s RHHBY Avastin (bevacizumab) improves outcomes in patients with EGFRvIII-positive, recurrent GBM across multiple measures.
In the study, patients were randomized into two treatment arms: Rintega plus Avastin or a control agent plus Avastin. Moreover, patients were Avastin-naïve at the startning of the study. Results demonstrated that Rintega met the six-month primary endpoint of progression free survival (PFS6). At six months, 28% of these patients receiving Rintega did not progress on the disease as contrast to 16% in the controlled arm. Additionally, a statistically noteworthyoverall survival benefit was also observed in the Rintega arm. The Rintega group registered a median overall survival rate of 11.6 months contrast with 9.3 months in the control arm.
In addition to this, Rintega showed superiority across multiple other important endpoints counting long-term progression-free survival, objective response rate and need for steroids. On the safety front, Rintega was found to be very well tolerated without additional toxicity to Avastin.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.
Novo Nordisk A/S (ADR) (NYSE:NVO), during its Wednesday’s current trading session gained 0.56% to $57.70.
Novo Nordisk A/S (ADR) (NVO) declared that the SCALE Obesity and Prediabetes three-year extension study on Saxenda has met its primary endpoint. The study was conducted in adults who were obese or were overweight with co morbidities and had prediabetes at baseline.
The randomized, blinded, three-year extension study showed that continued treatment with Saxenda in combination with a low-calorie diet and raised physical activity led to a delay in onset of type II diabetes contrast to placebo (in combination with diet and exercise). The time-to-onset of type II diabetes was 2.6 times longer in patients undergoing treatment with Saxenda contrast to those receiving placebo. Moreover, the risk of developing the disease was cut down by about 80% in the Saxenda arm.
Additionally, Novo Nordisk revealed data related to weight loss of patients in the SCALE Obesity and Prediabetes three-year extension study. At 160 weeks, on an average Saxenda led to a weight loss of 6.1% from baseline, contrast to only 1.8% for placebo, both in combination with a low-calorie diet and raised physical activity. Notably, 24.3% of the patients lost over 10% of their body weight under treatment with Saxenda contrast to 9.4% of those in the placebo arm.
According to the American Medical Association, obesity is a disease that requires long-term administration and is associated with various serious health consequences counting type II diabetes. In this scenario, results from the three-year extension study demonstrating Saxenda’s efficacy in delaying the occurrence and reducing the risk of type II diabetes are encouraging.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
